Skip to main content
Premium Trial:

Request an Annual Quote

NIH Seeks New Technologies, Computational Tools for Human Microbiome Project

NEW YORK (GenomeWeb News) – The National Institutes of Health has issued several new funding opportunities aimed at developing technologies for studying the genomes of microbial communities that inhabit the human body.
On Friday, NIH issued five requests for applications related to the Human Microbiome Project, which aims to understand the genomics of human microbiota and analyze its role in human health and disease.
The RFAs follow NIH’s announcement earlier this month that it plans to award up to $28 million over four years to demonstration projects under the Human Microbiome Project initiative.
One set of grants announced on Friday will fund the creation of a Data Analysis and Coordination Center for the Human Microbiome Project, a portal that will provide access to the data and tools created by the project.
Total funding for the DACC award is more than $2 million for each of five years.
Another set of grants will provide a total of around $1.5 million to support the development of computational tools that can be used to analyze and interpret data generated in the HMP.
NIH has issued two separate RFAs for this initiative under its R01 and R21 award mechanisms. NIH expects to award between one and four R01 grants of up to three years and between two and four R21 grants for up to two years.
Another pair of grants, also provided through the R01 and R21 award programs, is seeking new technologies for obtaining samples for sequencing, “by culturing or otherwise isolating for analysis currently uncultivatable organisms from the human microbiota.”
NIH plans to award a total of $2 million for these awards. NIH will award between two and four R01 grants for up to three years and between two and six R21 grants for up to two years.
Applications for all of the HMP grants are due Feb. 15, 2008.  

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.